News from IIR members: Air Liquide

Air Liquide and VitalAire are launching a new, personalized support programme for sleep apnoea patients. This disorder affects 1.5 million people in France, and 5% of the world's adult population. Eight out of 10 persons suffering from this condition are unaware of it. Untreated sleep apnoea multiplies by six the risk of road accidents and coronary accidents and it can lead to numerous other disorders (diabetes, metabolic syndrome, depression, behavioral problems, etc.). The standard treatment for is Continuous Positive Airway Pressure (CPAP), and is provided in the patient's home.